Figure 3.
Validation analysis of the candidate proteins. Immunoblots of TBB2C and VIM. (A) Relative expression of TBB2C in different OC stages compared to benign controls and healthy subjects (ns, non significant; *p-value, 0.01; ***p-value, 0.0004; ****p-value < 0.0001). (B) ROC curve displaying TBB2C sensitivity to distinguish OC from benign controls and healthy subjects, and benign controls from healthy subjects (C).
